Business Daily.
.
A+ R A-

Walvax Biotechnology Selects Medidata’s Cloud-Based Platform to Advance Pediatric Vaccine Program in China

E-mail Print PDF
NEW YORK--(BUSINESS WIRE)--Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that its industry-leading technology platform has been adopted by Walvax Biotechnology Co., Ltd (“Walvax”) (SZSE: 300142), a biopharmaceutical company in China. Walvax is harnessing the Medidata Clinical Cloud® platform to improve data management activities and drive biomedical innovation in the development of a pneumococcal conjugate v

imageimage

Read more

Grow Your Business with Times Media
Business Daily Media